Objective:  To   describe   the   clinical   features   and   the   result   of   transarterial chemoembolization   (TACE)   in   primary   hepato   -   cellular   carcinoma   at   Thainguyen national hospital from August 2016 to August 2020. Subject and method: 58 patients who   diagnosed   with   hepato-cellular   carcinoma   (HCC)   were   treated   by   TACE   at Thainguyen national hospital from August 2016 to August 2020.Result:The average age of patients was 56.4 ± 11.9 years old. The location of tumors was mainly in the right lobe of liver, accounting for 82.8%. The average size of the tumors was 7.5 ± 3.2cm.   The   group   of   patients   with   tumor’s   size   from   5cm   to   10cm   accounted   for 44.8%. After 1 month, 26.3% of patients still had right hypochondrium pain compared with   58.6%   before   embolization.   The   average   size   of   the   tumors   before   the embolization was 71.2 ± 27.5mm, and after 1 month, The average size was 67.9 ± 25.9mm. The mean overall survival (OS) was 20.8 ± 1.9 months (95% CI: 17.2 - 24.5).The   OS   after   6   months,   12   months,   24   months   were   91.2%,   76.3%,   30.5% respectively. Patients with tumor’s size  < 5cm had mean survival time of 26.1 ± 3.2 months, while the group of patients with tumors > 10cm had a shortest mean survival time (p<0.001). The mean survival time of the group of patients who had with 2 or more TACE times was 31.3 ± 4.1 months, which was statistically significantly higher than the group of patients with only one time of TACE (16.9 ± 1.5 months) (p=0.002). Conclusion:   TACE   was   an   effective   treatment   for   HCC   patients.   The   outcome   was better in the group of patients with tumor’s size under 5 cm. Additional TACE also resulted in higher treatment efficacy for HCC patients.

Keywords:   Hepatocellular   carcinoma,   transarterial   chemoembolization,   overall survival, clinical features.